Skip to content
OpenCapital
Get started

Acadia Pharmaceuticals ACAD Proceeds From Sale And Maturity Of Available For Sale Securities

Proceeds From Sale And Maturity Of Available For Sale Securities at other companies

Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
——
BridgeBio Pharma logo
BridgeBio PharmaBBIO
——
Crinetics Pharmaceuticals logo
Crinetics PharmaceuticalsCRNX
——
Travere Therapeutics, Inc. logo
Travere Therapeutics, Inc.TVTX
——

Other financials

Income statement

See full
Revenue$268.1M+9.7%
Gross profit$243.3M+8.6%
Operating income-$4.6M-124%
Net income$3.6M-80.8%
EPS (diluted)$0.02-81.8%

Balance sheet

See full
Cash & equivalents$282.2M+29.6%
Total debt$50.8M-9.3%
Total equity$1.2B+63.1%
Total assets$1.6B+41.8%

Cash flow

See full
Operating cash flow$34.0M+67.2%
CapEx$5.2M—
Free cash flow$28.8M+41.6%

Valuation

See full
Market cap$3.87B+37.0%

Profitability

See full
Gross margin91.5%-0.6pp
Operating margin7.4%-16.2pp
Net margin34.3%+11.3pp
FCF margin18.9%—

Returns & leverage

See full
Return on equity37.3%+0.1pp
Debt / equity0×0.0×
Current ratio3.6×+0.7×

Where this comes from

Reported directly by Acadia Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities.

The official record: Acadia Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Acadia Pharmaceuticals's proceeds from sale and maturity of available for sale securities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Acadia Pharmaceuticals's proceeds from sale and maturity of available for sale securities?
Acadia Pharmaceuticals (ACAD) reported proceeds from sale and maturity of available for sale securities of $86.5M in Q1 2026.
How has Acadia Pharmaceuticals's proceeds from sale and maturity of available for sale securities changed year-over-year?
Acadia Pharmaceuticals's proceeds from sale and maturity of available for sale securities decreased by 33.9% year-over-year, from $130.8M to $86.5M.
What is the long-term trend for Acadia Pharmaceuticals's proceeds from sale and maturity of available for sale securities?
Over 4 years (2021 to 2025), Acadia Pharmaceuticals's proceeds from sale and maturity of available for sale securities has grown at a 3.9% compound annual growth rate (CAGR), from $422.82M to $493.53M.